218 related articles for article (PubMed ID: 20876800)
1. Aerobic glycolysis suppresses p53 activity to provide selective protection from apoptosis upon loss of growth signals or inhibition of BCR-Abl.
Mason EF; Zhao Y; Goraksha-Hicks P; Coloff JL; Gannon H; Jones SN; Rathmell JC
Cancer Res; 2010 Oct; 70(20):8066-76. PubMed ID: 20876800
[TBL] [Abstract][Full Text] [Related]
2. Oncogenic stress induced by acute hyper-activation of Bcr-Abl leads to cell death upon induction of excessive aerobic glycolysis.
Dengler MA; Staiger AM; Gutekunst M; Hofmann U; Doszczak M; Scheurich P; Schwab M; Aulitzky WE; van der Kuip H
PLoS One; 2011; 6(9):e25139. PubMed ID: 21949869
[TBL] [Abstract][Full Text] [Related]
3. Imatinib mesylate induces cisplatin hypersensitivity in Bcr-Abl+ cells by differential modulation of p53 transcriptional and proapoptotic activity.
Skorta I; Oren M; Markwardt C; Gutekunst M; Aulitzky WE; van der Kuip H
Cancer Res; 2009 Dec; 69(24):9337-45. PubMed ID: 19934315
[TBL] [Abstract][Full Text] [Related]
4. Requirement for Mdm2 in the survival effects of Bcr-Abl and interleukin 3 in hematopoietic cells.
Goetz AW; van der Kuip H; Maya R; Oren M; Aulitzky WE
Cancer Res; 2001 Oct; 61(20):7635-41. PubMed ID: 11606405
[TBL] [Abstract][Full Text] [Related]
5. Glucose metabolism attenuates p53 and Puma-dependent cell death upon growth factor deprivation.
Zhao Y; Coloff JL; Ferguson EC; Jacobs SR; Cui K; Rathmell JC
J Biol Chem; 2008 Dec; 283(52):36344-53. PubMed ID: 18990690
[TBL] [Abstract][Full Text] [Related]
6. Adhesion to fibronectin selectively protects Bcr-Abl+ cells from DNA damage-induced apoptosis.
van der Kuip H; Goetz AW; Miething C; Duyster J; Aulitzky WE
Blood; 2001 Sep; 98(5):1532-41. PubMed ID: 11520804
[TBL] [Abstract][Full Text] [Related]
7. A Bcr/Abl-independent, Lyn-dependent form of imatinib mesylate (STI-571) resistance is associated with altered expression of Bcl-2.
Dai Y; Rahmani M; Corey SJ; Dent P; Grant S
J Biol Chem; 2004 Aug; 279(33):34227-39. PubMed ID: 15175350
[TBL] [Abstract][Full Text] [Related]
8. BCR/ABL recruits p53 tumor suppressor protein to induce drug resistance.
Stoklosa T; Slupianek A; Datta M; Nieborowska-Skorska M; Nowicki MO; Koptyra M; Skorski T
Cell Cycle; 2004 Nov; 3(11):1463-72. PubMed ID: 15492510
[TBL] [Abstract][Full Text] [Related]
9. BCR/ABL activates mdm2 mRNA translation via the La antigen.
Trotta R; Vignudelli T; Candini O; Intine RV; Pecorari L; Guerzoni C; Santilli G; Byrom MW; Goldoni S; Ford LP; Caligiuri MA; Maraia RJ; Perrotti D; Calabretta B
Cancer Cell; 2003 Feb; 3(2):145-60. PubMed ID: 12620409
[TBL] [Abstract][Full Text] [Related]
10. Comparison of effects of the tyrosine kinase inhibitors AG957, AG490, and STI571 on BCR-ABL--expressing cells, demonstrating synergy between AG490 and STI571.
Sun X; Layton JE; Elefanty A; Lieschke GJ
Blood; 2001 Apr; 97(7):2008-15. PubMed ID: 11264165
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of wild-type and mutant Bcr-Abl by AP23464, a potent ATP-based oncogenic protein kinase inhibitor: implications for CML.
O'Hare T; Pollock R; Stoffregen EP; Keats JA; Abdullah OM; Moseson EM; Rivera VM; Tang H; Metcalf CA; Bohacek RS; Wang Y; Sundaramoorthi R; Shakespeare WC; Dalgarno D; Clackson T; Sawyer TK; Deininger MW; Druker BJ
Blood; 2004 Oct; 104(8):2532-9. PubMed ID: 15256422
[TBL] [Abstract][Full Text] [Related]
12. Pml and TAp73 interacting at nuclear body mediate imatinib-induced p53-independent apoptosis of chronic myeloid leukemia cells.
Liu JH; Liu CC; Yen CC; Gau JP; Wang WS; Tzeng CH
Int J Cancer; 2009 Jul; 125(1):71-7. PubMed ID: 19291793
[TBL] [Abstract][Full Text] [Related]
13. BCR/ABL regulates expression of the cyclin-dependent kinase inhibitor p27Kip1 through the phosphatidylinositol 3-Kinase/AKT pathway.
Gesbert F; Sellers WR; Signoretti S; Loda M; Griffin JD
J Biol Chem; 2000 Dec; 275(50):39223-30. PubMed ID: 11010972
[TBL] [Abstract][Full Text] [Related]
14. Increased acetylation of lysine 317/320 of p53 caused by BCR-ABL protects from cytoplasmic translocation of p53 and mitochondria-dependent apoptosis in response to DNA damage.
Kusio-Kobialka M; Wolanin K; Podszywalow-Bartnicka P; Sikora E; Skowronek K; McKenna SL; Ghizzoni M; Dekker FJ; Piwocka K
Apoptosis; 2012 Sep; 17(9):950-63. PubMed ID: 22696202
[TBL] [Abstract][Full Text] [Related]
15. Akt requires glucose metabolism to suppress puma expression and prevent apoptosis of leukemic T cells.
Coloff JL; Mason EF; Altman BJ; Gerriets VA; Liu T; Nichols AN; Zhao Y; Wofford JA; Jacobs SR; Ilkayeva O; Garrison SP; Zambetti GP; Rathmell JC
J Biol Chem; 2011 Feb; 286(7):5921-33. PubMed ID: 21159778
[TBL] [Abstract][Full Text] [Related]
16. The novel anticancer agent JNJ-26854165 is active in chronic myeloid leukemic cells with unmutated BCR/ABL and T315I mutant BCR/ABL through promoting proteosomal degradation of BCR/ABL proteins.
You L; Liu H; Huang J; Xie W; Wei J; Ye X; Qian W
Oncotarget; 2017 Jan; 8(5):7777-7790. PubMed ID: 27999193
[TBL] [Abstract][Full Text] [Related]
17. Enhancement of imatinib-induced apoptosis of BCR/ABL-expressing cells by nutlin-3 through synergistic activation of the mitochondrial apoptotic pathway.
Kurosu T; Wu N; Oshikawa G; Kagechika H; Miura O
Apoptosis; 2010 May; 15(5):608-20. PubMed ID: 20094798
[TBL] [Abstract][Full Text] [Related]
18. Alterations in gene expression and sensitivity to genotoxic stress following HdmX or Hdm2 knockdown in human tumor cells harboring wild-type p53.
Heminger K; Markey M; Mpagi M; Berberich SJ
Aging (Albany NY); 2009 Jan; 1(1):89-108. PubMed ID: 19946469
[TBL] [Abstract][Full Text] [Related]
19. BCR-ABL and constitutively active erythropoietin receptor (cEpoR) activate distinct mechanisms for growth factor-independence and inhibition of apoptosis in Ba/F3 cell line.
Ahmed M; Dusanter-Fourt I; Bernard M; Mayeux P; Hawley RG; Bennardo T; Novault S; Bonnet ML; Gisselbrecht S; Varet B; Turhan AG
Oncogene; 1998 Jan; 16(4):489-96. PubMed ID: 9484838
[TBL] [Abstract][Full Text] [Related]
20. Compensatory PI3-kinase/Akt/mTor activation regulates imatinib resistance development.
Burchert A; Wang Y; Cai D; von Bubnoff N; Paschka P; Müller-Brüsselbach S; Ottmann OG; Duyster J; Hochhaus A; Neubauer A
Leukemia; 2005 Oct; 19(10):1774-82. PubMed ID: 16136169
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
